Sanofi, Selecta sign allergy immunotherapy deal worth up to $900M

11/29/2012 | Genetic Engineering & Biotechnology News · Reuters

Sanofi agreed to use Selecta Biosciences' vaccine technology to develop one immunotherapy for a life-threatening food allergy, with an option to develop two more treatments. The deal entitles Selecta to as much as $300 million in preclinical, clinical, regulatory and sales milestone payments for each allergen indication, for as many as three immunotherapy candidates, plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC